Pharmaceuticals & Biotechnology

LIGAND PHARMACEUTICALS INC CEO pay

Tavo Espinoza, Chief Executive Officer. Fiscal year 2025, as reported to the SEC.

Total compensation

$4.4M

$4,382,148 for fiscal 2025: the Summary Compensation Table total, with stock and option awards at their grant-date value.

Definitive proxy statement, filed 2026-04-21SEC accession number 0000886163-26-000021

In context

The median chief executive among 61 Pharmaceuticals & Biotechnology companies with $100M – $500M in revenue was paid $3.2M. The middle half ranged from $1.9M to $4.2M.

Tavo Espinoza's total is above that median.

See how your pay compares to LIGAND PHARMACEUTICALS INC's peers

CEOSalary breaks this total into salary, bonus, stock and option awards, builds a peer set of comparable companies around it, and places your own package against them, with every figure cited to its filing.

Start a 3-day trial

Source: LIGAND PHARMACEUTICALS INC's definitive proxy statement (SEC Form DEF 14A), Summary Compensation Table, fiscal year 2025. Figures are as reported by the company and are not adjusted or estimated. Context figures are from CEOSalary's snapshot of SEC filings as of 2026-10-28. Not financial, legal or compensation-consulting advice.